Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis.
Leukocyte infiltration into the liver is paramount to the development of liver injury in hepatitis. Hepatitis occurring after the administration of Con A in mice is felt to be a T lymphocyte-mediated disease. In this study, we report that neutrophils are the key initiators of lymphocyte recruitment and liver injury caused by Con A. The objectives of this study were to investigate the involvement of neutrophils in Con A-induced hepatitis in vivo via intravital microscopy. After Con A administration, we observed a significant increase in leukocyte rolling flux, a decrease in rolling velocity, and an increase in leukocyte adhesion to the hepatic microvasculature. Fluorescence microscopy identified that within 4 h of Con A administration only a minority of the recruited leukocytes were T lymphocytes. Furthermore, immunohistochemistry showed a significant increase in neutrophils recruited to the liver post-Con A treatment in association with liver cell damage, as reflected by elevated serum alanine aminotransferase levels. Using flow cytometry, we observed that Con A could bind directly to neutrophils, which resulted in a shedding of L-selectin, an increase in beta(2)-integrin expression, and the production of reactive oxidants. Following neutrophil depletion, a significant inhibition of Con A-induced CD4+ T lymphocyte recruitment to the liver resulted and complete reduction in hepatic injury, as assessed by serum alanine aminotransferase levels. In summary, the present data support the concept that neutrophils play an important and previously unrecognized role in governing Con A-induced CD4+ T cell recruitment to the liver and the subsequent development of hepatitis.
Bonder
Claudine S
CS
Immunology Research Group, Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada.
Ajuebor
Maureen N
MN
Zbytnuik
Lori D
LD
Kubes
Paul
P
Swain
Mark G
MG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D002465:Cell Movement / Q000276:immunology; D003208:Concanavalin A / Q000008:administration & dosage* / Q000378:metabolism; D015536:Down-Regulation / Q000276:immunology; D006520:Hepatitis, Animal / Q000276:immunology* / Q000473:pathology* / Q000517:prevention & control; D007275:Injections, Intravenous; D008099:Liver / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008856:Microscopy, Fluorescence; D018715:Microscopy, Video; D009503:Neutropenia / Q000276:immunology; D018375:Neutrophil Activation / Q000276:immunology; D020556:Neutrophil Infiltration / Q000276:immunology*; D009504:Neutrophils / Q000378:metabolism / Q000473:pathology; D016877:Oxidants / Q000096:biosynthesis; D011485:Protein Binding / Q000276:immunology; D017382:Reactive Oxygen Species / Q000378:metabolism
D000911:Antibodies, Monoclonal; D016877:Oxidants; D017382:Reactive Oxygen Species; D003208:Concanavalin A